Orthofix Medical Inc.
Close on Oct 19, 2026
- Market cap
- $392.29M
- P/E (TTM)
- –
- Dividend yield
- –
About Orthofix Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Orthofix Medical Inc. operates as a medical technology enterprise focused on spine care and limb reconstruction therapies. The company delivers an array of spinal and orthopedic solutions through key segments that include Global Spine and Global Limb Reconstruction. Its core product portfolio encompasses spinal implants, bone growth therapies, specialized biologics, enabling surgical technologies, and limb reconstruction devices designed to treat complex bone and musculoskeletal conditions. The company primarily serves surgeons, physicians, hospitals, and broader healthcare facilities, with its products and procedures utilized by patients requiring specialized orthopedic interventions.
The company operates globally across several international markets, conducting business and maintaining operations in countries including the United States, France, Italy, Germany, Australia, the United Kingdom, Brazil, the Netherlands, and Switzerland. Orthofix Medical Inc. maintains its principal executive offices and corporate headquarters in Lewisville, Texas.
Summary of the business section of Orthofix Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Orthofix Medical Inc.
- Headquarters
- Lewisville, TX
- Address
- 3451 Plano Parkway 75056
- Phone
- (214) 937-2000
- Employees
- 1,605, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 23
- Auditor
- Ernst & Young LLP, Dallas, Texas
Stock & identifiers
- Ticker
- OFIX
- Exchange
- Nasdaq
- Shares outstanding
- 41M, Jul 31, 2026
- Public float
- $440.20M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 884624
- CUSIP
- 68752M108
- ISIN
- US68752M1080
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Massimo Calafiore | President & CEO, Director | 320,136 |
| Patrick Fisher | President, Global Limb Recon | 51,069 |
| Aviva McPherron | Pres, Global Ops & Qual | 66,330 |
| Jorge Andres Cedron | CLO | 59,006 |
| Lucas Vitale | CP&BOO | 160,449 |
| Max Reinhardt | President, Global Spine | 25,348 |
| Julie Andrews | CFO | 88,746 |
| Geoffrey C. Gillespie | CAO | 42,445 |
| Alan Lee Bazaar | Director | 65,489 |
| Michael E. Paolucci | Director | 102,727 |
| Charles R. Kummeth | Director | 76,305 |
| Jason Hannon | Director | 87,662 |
| Vickie L. Capps | Director | 43,300 |
| Michael Finegan | Director | 81,617 |
| Wayne Burris | Director | 65,504 |
| Shweta Maniar | Director | 69,038 |
| John B. Henneman Iii | Director | 105,774 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Catherine Burzik | $0 | – | $2.17M | $35 | $104 |
| FY2025 Massimo Calafiore | $7.31M | $3.28M | $2.17M | $35 | $104 |
| FY2024 Catherine Burzik | $41.80K | $94.78K | $2.69M | $38 | $150 |
| FY2024 Massimo Calafiore | $10.63M | $14.63M | $2.69M | $38 | $150 |
| FY2023 Catherine Burzik | $2.62M | $2.58M | $2.28M | $29 | $130 |
| FY2023 Jon CSerbousek | $15.63M | $2.34M | $2.28M | $29 | $130 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,605 employees worldwide.”
Corporate history
Events identified from SEC filings